| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1052715288 |
| P356 | DOI | 10.1038/BMT.2013.42 |
| P698 | PubMed publication ID | 23562971 |
| P5875 | ResearchGate publication ID | 236127707 |
| P2093 | author name string | S Takahashi | |
| H Ogawa | |||
| T Yamaguchi | |||
| R Suzuki | |||
| T Fukuda | |||
| Y Morishima | |||
| K Kato | |||
| M Kurokawa | |||
| J Tanaka | |||
| H Akiyama | |||
| H Sakamaki | |||
| Y Atsuta | |||
| S Taniguchi | |||
| K Miyamura | |||
| T Eto | |||
| T Nagamura-Inoue | |||
| K Kawa | |||
| K Yakushijin | |||
| S Kurosawa | |||
| P2860 | cites work | Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome | Q28374952 |
| Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. | Q34049208 | ||
| Conditioning regimens for allogeneic stem cell transplants | Q34072393 | ||
| Reducing transplant toxicity | Q34404019 | ||
| Reduced mortality after allogeneic hematopoietic-cell transplantation | Q34472861 | ||
| Age and acute myeloid leukemia | Q34564663 | ||
| High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation | Q34582448 | ||
| High-dose daunorubicin in older patients with acute myeloid leukemia | Q34612117 | ||
| Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. | Q34637551 | ||
| Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? | Q34743469 | ||
| Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research | Q35031141 | ||
| Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation | Q35665096 | ||
| Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality | Q36715387 | ||
| Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia | Q37104236 | ||
| Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. | Q37140698 | ||
| Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia | Q37353919 | ||
| Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need | Q37933833 | ||
| Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults | Q37968584 | ||
| Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time | Q38472178 | ||
| Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies | Q38486334 | ||
| Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors | Q43212283 | ||
| Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation | Q43710389 | ||
| Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations | Q44253438 | ||
| Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. | Q44471803 | ||
| Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry. | Q44706384 | ||
| Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity | Q46819255 | ||
| High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group | Q46847866 | ||
| Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation | Q46913129 | ||
| Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome | Q47359749 | ||
| Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. | Q54643257 | ||
| Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study | Q58789014 | ||
| Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation | Q80001093 | ||
| Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study | Q80151067 | ||
| Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients | Q80237552 | ||
| Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted | Q80249976 | ||
| Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years | Q83508614 | ||
| Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation | Q84192368 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 1198-1204 | |
| P577 | publication date | 2013-04-08 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia | |
| P478 | volume | 48 |
| Q40122841 | Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation |
| Q52877010 | Blood glucose control using a computer-guided glucose management system in allogeneic hematopoietic cell transplant recipients. |
| Q48119892 | Danaparoid reduces transplant-related mortality in stem cell transplantation for children |
| Q90459507 | Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation |
| Q51210755 | Low-dose anti-thymocyte globulin reduce severe acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. |
| Q48031906 | Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia |
| Q39049349 | Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT. |
| Q95492321 | Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis |
| Q40129891 | Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT. |
| Q40288619 | Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. |
| Q36549460 | Spiritual Well-Being in Hispanic and Non-Hispanic Survivors of Allogeneic Hematopoietic Stem Cell Transplantation |
Search more.